Multivariable logistic regression model assessing factors associated with severe infections in patients diagnosed with CLL (N = 3960)
| Variable . | OR . | 95% CI . | P value . |
|---|---|---|---|
| IgG testing∗ | |||
| No IgG testing | Reference | ||
| 1 | 0.36 | (0.29-0.44) | <.0001† |
| 2 | 0.23 | (0.17-0.31) | <.0001† |
| ≥3 | 0.08 | (0.06-0.10) | <.0001† |
| IgRT use∗ | 0.52 | (0.28-0.97) | .038† |
| Chemotherapy‡,§ | 2.39 | (1.85-3.09) | <.0001† |
| mAb‡ | 1.27 | (0.99-1.61) | .058 |
| Targeted therapy‡ | 2.49 | (2.03-3.06) | <.0001† |
| Immunomodulatory drug‡ | 3.76 | (1.82-7.80) | .0004† |
| Corticosteroid‡ | 5.46 | (4.42-6.75) | <.0001† |
| HSCT‡ | 4.12 | (2.73-6.22) | <.0001† |
| CAR-T cell therapy‡ | 3.30 | (1.66-6.57) | .001† |
| Age | 1.02 | (1.08-1.02) | .0001† |
| Sex | |||
| Male | Reference | ||
| Female | 0.84 | (0.71-1.00) | .054† |
| Variable . | OR . | 95% CI . | P value . |
|---|---|---|---|
| IgG testing∗ | |||
| No IgG testing | Reference | ||
| 1 | 0.36 | (0.29-0.44) | <.0001† |
| 2 | 0.23 | (0.17-0.31) | <.0001† |
| ≥3 | 0.08 | (0.06-0.10) | <.0001† |
| IgRT use∗ | 0.52 | (0.28-0.97) | .038† |
| Chemotherapy‡,§ | 2.39 | (1.85-3.09) | <.0001† |
| mAb‡ | 1.27 | (0.99-1.61) | .058 |
| Targeted therapy‡ | 2.49 | (2.03-3.06) | <.0001† |
| Immunomodulatory drug‡ | 3.76 | (1.82-7.80) | .0004† |
| Corticosteroid‡ | 5.46 | (4.42-6.75) | <.0001† |
| HSCT‡ | 4.12 | (2.73-6.22) | <.0001† |
| CAR-T cell therapy‡ | 3.30 | (1.66-6.57) | .001† |
| Age | 1.02 | (1.08-1.02) | .0001† |
| Sex | |||
| Male | Reference | ||
| Female | 0.84 | (0.71-1.00) | .054† |
Patients diagnosed with CLLL: n = 3960.
HSCT, hematopoietic stem cell transplantation.
For patients having an infection, IgG testing and IgRT use were measured in the 12 months before the date of infection.
P < .05 were considered to be significant.
Assessed at any time point because dates are not available in the clinical notes.
In the univariate logistic regression model, patients receiving chemotherapy had significantly higher likelihood of hypogammaglobulinemia (OR, 3.98; 95% CI, 3.37-4.70; P < .0001) compared to patients who never received chemotherapy.